In their ongoing quest to develop and monetize treatments more quickly and efficiently, pharmaceutical companies are partnering with outsourcers throughout their value chains. As a result, the outsourced pharmaceutical services sector provides wide-ranging opportunities for strategic acquirers and private equity investors. (See our full series covering M&A opportunities across outsourced pharma services.)

A Flurry of M&A Activity

Clinical trial sites are positioned for sustained growth due to an expanding U.S. pre-clinical pipeline, a steady rise in pharmaceutical R&D spend, and increasing trial complexity. With these drivers in place, the estimated $16 billion U.S. clinical trial site market is expected to grow at 6.8% CAGR through 2025. [1]

Despite being a critical link of the value chain for clinical trials, the subsector is highly fragmented and predominantly includes small, founder-run businesses. A need for consolidation and professionalization exists to create efficiencies and cost savings in the clinical trial process.

The enduring trends, growth trajectory, and fragmentation of clinical trial sites have caught the eye of investors, resulting in a flurry of high-profile M&A activity. Ten notable platforms were acquired or created since 2021, and the market is poised for accelerated consolidation going forward.

Here, senior professionals from our Healthcare & Life Sciences Group share key insights into the clinical trial site space, including:

• Deep dives into the subsector’s growth drivers 

• Critical success factors of best-in-class businesses 

• A detailed look at the clinical trial site landscape 
  

To discuss burgeoning M&A opportunities within the clinical trial sites subsector or broader outsourced pharma services space, please contact our senior professionals.

1. HealthAdvances